초록 ▼

The present invention is an apparatus and a method for delivery of mitomycin through an eluting biocompatible implantable medical device. A biocompatible drug release matrix comprises a biocompatible drug release matrix and a drug incorporated into the biocompatible drug release matrix. The drug has

The present invention is an apparatus and a method for delivery of mitomycin through an eluting biocompatible implantable medical device. A biocompatible drug release matrix comprises a biocompatible drug release matrix and a drug incorporated into the biocompatible drug release matrix. The drug has antibiotic and anti-proliferative properties and is an analogue related to the quinone-containing alkylating agents of a mitomycin family. The drug is initially released from the biocompatible drug release matrix at a faster rate followed by a release at a slower rate. The drug release rate maintains tissue level concentrations of the drug for at least two weeks after implantation of the medical device. The present invention provides a coating for a vascular prosthesis that elutes the drug at a controlled rate to inhibit proliferation of smooth muscle cells causing restenosis.

대표청구항 ▼

What is claimed is: 1. A biocompatible drug release matrix for a medical device comprising: a biocompatible polymer matrix comprising a thermoplastic polyurethane elastomer; and a drug incorporated into the biocompatible polymer matrix, wherein the biocompatible polymer matrix is co-solubilized wi

What is claimed is: 1. A biocompatible drug release matrix for a medical device comprising: a biocompatible polymer matrix comprising a thermoplastic polyurethane elastomer; and a drug incorporated into the biocompatible polymer matrix, wherein the biocompatible polymer matrix is co-solubilized with the drug in a solvent to form a solution wherein the drug forms a plurality of small particles in the solution and the solvent is evaporated from the solution. 2. The biocompatible drug release matrix of claim 1 wherein the drug has antibiotic properties and anti-proliferative properties. 3. The biocompatible drug release matrix of claim 1 wherein the drug is an analogue related to the quinone-containing alkylating agents of a mitomycin family. 4. The biocompatible drug release matrix of claim 1 wherein the drug is mitomycin C. 5. The biocompatible drug release matrix of claim 1 wherein a ratio of the weight of the biocompatible polymer matrix and the drug is about 4 to about 1. 6. The biocompatible drug release matrix of claim 1 wherein the solvent is selected from the group consisting of water, saline, tetrahydrofuran, methanol, acetone, butyl acetate, cyclohexane, carbon tetrachloride, ether, chloroform, benzene, ethanol, toluene, dimethyl sulfoxide, petroleum ethers, other hydrocarbons and other organic solvents. 7. The biocompatible drug release matrix of claim 1 wherein the biocompatible polymer matrix further comprises polyvinyl pyrrolidone with an at least one isocyanate. 8. The biocompatible drug release matrix of claim 1 wherein the biocompatible polymer matrix further comprises a mixture of hydrophilic and hydrophobic polymers selected from the group consisting of polyurethanes, polyvinyl pyrrolidone, poly methyl methracrylate (PMMA), hydroxyetyl methacrylate and cellulose esters. 9. The biocompatible drug release matrix of claim 1 wherein the biocompatible polymer matrix further comprises an erodible polymer. 10. The biocompatible drug release matrix of claim 9 wherein the erodible polymer is selected from the group consisting of polyactide, polyactide with glycolide, polyester-amides, polyurethanes, poly(ethylene-urethane), poly(ester-urethane) and poly(ether-polyester-urethane), amino-acid based polyurethanes, polycaprolactone based polyurethanes, polyurethanes synthesized from poly(butylene succinate) polyol, poly(ethylene glycol), and 4,4'-methylenebis(cyclohexyl isocyanate), fat, carbohydrates and protein compounds. 11. The biocompatible drug release matrix of claim 1 wherein the biocompatible polymer matrix further comprises parylene and derivatives of parylene. 12. The biocompatible drug release matrix of claim 1 wherein the biocompatible polymer matrix further comprises polybutylmethacrylate and polyethylenevinylacetate. 13. The biocompatible drug release matrix of claim 12 wherein the concentrations of polybutylmethacrylate and polyethylenevinylacetate are approximately equal. 14. The biocompatible drug release matrix of claim 1 wherein the biocompatible polymer matrix further comprises a polymer selected from the group consisting of hybrid polymers, composites and polymer blends, acrylate terpolymers, tri-block polymers, polyethylene vinyl-acetate methacrylic tri-block terpolymer, ethyl-vinyl acetate, polyethyl vinyl-acetate, polybutyl methacrylic acid and polyethyl vinyl-acetate blends, polyurethanes and polyurethane-polycarbonate blends, silicone-urethane copolymers, polyvinyl pyrrolidone, polyester resins and parylene. 15. A biocompatible drug release matrix for a medical device comprising: a biocompatible drug eluting matrix comprising polybutylmethacrylate and polvethylenevinylacetate; and a drug incorporated into the biocompatible drug eluting matrix, wherein the drug is an analogue related to the quinone-containing alkylating agents of a mitomycin family and wherein the drug forms a plurality of small particles in a solution. 16. The biocompatible drug release matrix of claim 15 wherein the drug is mitomycin C. 17. The biocompatible drug release matrix of claim 15 wherein the biocompatible drug eluting matrix releases the drug at a rate sufficient to maintain tissue level concentrations of the drug from about 0.01 micrograms per milliliter to about 25 micrograms per milliliter of the surrounding tissue for at least two weeks after implantation of the medical device. 18. The biocompatible drug release matrix of claim 15 wherein the biocompatible drug eluting matrix has a concentration of the drug between about 0.1 micrograms and about 101 micrograms per millimeter of medical device length. 19. The biocompatible drug release matrix of claim 15 wherein the biocompatible drug eluting matrix has a concentration of the drug between about 0.02 μg/mm2 and about 2.5 μg/mm2 per medical device surface area. 20. The biocompatible drug release matrix of claim 15 wherein the medical device is coated with a total dosage of about 10 micrograms of the drug per millimeter length of the medical device. 21. The biocompatible drug release matrix of claim 15 wherein the medical device is coated with a total dosage of about 0.5 micrograms to about 50 micrograms of the drug per millimeter length of the medical device. 22. The biocompatible drug release matrix of claim 15 wherein an initial dose of between about 10 percent to about 60 percent of the drug is delivered to the tissue in the first few days after implantation of the medical device. 23. The biocompatible drug release matrix of claim 15 wherein at least a portion of a remainder of the drug is delivered at a slower rate than an initial dose of the drug. 24. The biocompatible drug release matrix of claim 15 further comprising a burst control layer to reduce the rate of diffusion of the drug from the biocompatible drug release matrix. 25. The biocompatible drug release matrix of claim 15 wherein mitomycin C is eluted from the biocompatible drug release matrix at a controlled rate. 26. The biocompatible drug release matrix of claim 15 wherein the biocompatible drug release matrix is incorporated within a vascular prosthesis. 27. The biocompatible drug release matrix of claim 15 wherein the biocompatible drug release matrix comprises a coating applied to the surface of a vascular prosthesis. 28. The biocompatible drug release matrix of claim 15 wherein the biocompatible drug release matrix comprises a film which covers a vascular prosthesis. 29. The biocompatible drug release matrix of claim 15 wherein the biocompatible drug release matrix is co-solubilized with the drug in a solvent to form a solution and the solvent is evaporated from the solution. 30. The biocompatible drug release matrix of claim 15 further comprising polyvinyl pyrrolidone with an at least one isocyanate. 31. The biocompatible drug release matrix of claim 15 further comprising an erodible polymer. 32. The biocompatible drug release matrix of claim 15 wherein the erodible polymer is selected from the group consisting of polyactide, polyactide with glycolide, polyester-amides, polyurethanes, poly(ethylene-urethane), poly(ester-urethane) and poly(ether-polyester-urethane), amino-acid based polyurethanes, polycaprolactone based polyurethanes, polyurethanes synthesized from poly(butylene succinate) polyol, poly(ethylene glycol), and 4,4'-methylenebis(cyclohexyl isocyanate), fat, carbohydrates and protein compounds. 33. The biocompatible drug release matrix of claim 1 wherein the drug is linked to a compound to alter the release kinetics, decrease the toxicity or enhance the potency of the drug. 34. The biocompatible drug release matrix of claim 1 wherein the biocompatible polymer matrix comprises a plurality of sub-layers. 35. The biocompatible drug release matrix of claim 34 wherein the plurality of sub-layers have varying chemical compositions. 36. The biocompatible drug release matrix of claim 34 wherein an amount of the drug incorporated into the biocompatible polymer matrix varies from one sub-layer to an adjacent sub-layer. 37. The biocompatible drug release matrix of claim 34 wherein an amount of drug incorporated into the biocompatible polymer matrix is approximately the same from one sub-layer to an adjacent sub-layer. 38. The biocompatible drug release matrix of claim 34 wherein the plurality of sub-layers have the same chemical composition. 39. The biocompatible drug release matrix of claim 1 wherein the biocompatible polymer matrix comprises a single layer. 40. A biocompatible drug release matrix comprising: a biocompatible drug eluting matrix comprising a thermoplastic polyurethane elastomer; and a drug incorporated into the biocompatible drug eluting matrix, wherein the biocompatible drug eluting matrix is co-solubilized with the drug in a solvent to form a solution wherein the drug forms a plurality of small particles in the solution and the solvent is evaporated from the solution. 41. The biocompatible drug release matrix of claim 40 wherein the biocompatible drug eluting matrix comprises a plurality of sub-layers. 42. The biocompatible drug release matrix of claim 41 wherein an amount of drug incorporated into the biocompatible drug eluting matrix varies from one sub-layer to an adjacent sub-layer. 43. The biocompatible drug release matrix of claim 41 wherein an amount of drug incorporated into the biocompatible drug eluting matrix is approximately the same from one sub-layer to an adjacent sub-layer. 44. The biocompatible drug release matrix of claim 40 wherein the biocompatible drug eluting matrix comprises a single layer. 45. The biocompatible drug release matrix of claim 40 wherein the drug is linked to a compound to alter the release kinetics, decrease the toxicity or enhance the potency of the drug. 46. The biocompatible drug release matrix of claim 40 wherein the biocompatible drug release matrix is applied to a stent. 47. The biocompatible drug release matrix of claim 40 wherein the biocompatible drug release matrix is applied to a medical device. 48. The biocompatible drug release matrix of claim 47 wherein the biocompatible drug eluting matrix releases the drug at a rate sufficient to maintain tissue level concentrations of the drug from about 0.01 micrograms per milliliter to about 25 micrograms per milliliter of the surrounding tissue for at least two weeks after implantation of the medical device. 49. The biocompatible drug release matrix of claim 47 wherein the biocompatible drug eluting matrix has a concentration of the drug between about 0.1 micrograms and about 101 micrograms per millimeter of medical device length. 50. The biocompatible drug release matrix of claim 47 wherein the biocompatible drug eluting matrix has a concentration of the drug between about 0.02 μg/mm2 and about 2.5 μg/mm2 per medical device surface area. 51. The biocompatible drug release matrix of claim 47 wherein an initial dose of between about 10 percent to about 60 percent of the drug is delivered to the tissue in the first few days after implantation of the medical device. 52. The biocompatible drug release matrix of claim 40 wherein the drug has antibiotic properties and anti-proliferative properties. 53. The biocompatible drug release matrix of claim 40 wherein the drug is an analogue related to the quinone-containing alkylating agents of a mitomycin family. 54. The biocompatible drug release matrix of claim 40 wherein a ratio of the weight of the biocompatible drug eluting matrix and the drug is about 4 to about 1. 55. The biocompatible drug release matrix of claim 40 wherein the biocompatible drug eluting matrix further comprises polyvinyl pyrrolidone with an at least one isocyanate. 56. The biocompatible drug release matrix of claim 40 wherein the biocompatible drug eluting matrix further comprises a mixture of hydrophilic and hydrophobic polymers selected from the group consisting of polyurethanes, polyvinyl pyrrolidone, poly methyl methracrylate (PMMA), hydroxyetyl methacrylate and cellulose esters. 57. The biocompatible drug release matrix of claim 40 wherein the biocompatible drug eluting matrix further comprises an erodible polymer. 58. The biocompatible drug release matrix of claim 56 wherein the drug is entrapped into the mixture of hydrophilic and hydrophobic polymers of the biocompatible drug eluting matrix. 59. The biocompatible drug release matrix of claim 40 further comprising a metallic surface. 60. The biocompatible drug release matrix of claim 40 wherein the biocompatible drug eluting matrix further comprises polybutylmethacrylate and polyethylenevinylacetate. 61. The biocompatible drug release matrix of claim 40 wherein the drug remains part of the biocompatible drug eluting matrix. 62. The biocompatible drug release matrix of claim 40 wherein the biocompatible drug eluting matrix further comprises a polymer selected from the group consisting of hybrid polymers, composites and polymer blends, acrylate terpolymers, tri-block polymers, polyethylene vinyl-acetate methacrylic tri-block terpolymer, ethyl-vinyl acetate, polyethyl vinyl-acetate, polybutyl methacrylic acid and polyethyl vinyl-acetate blends, polyurethanes and polyurethane-polycarbonate blends, silicone-urethane copolymers, polyvinyl pyrrolidone, polyester resins and parylene. 63. A biocompatible drug release matrix comprising: a biocompatible polymer matrix comprising polybutylmethacrylate and polvethylenevinylacetate; and a drug suspended within the biocompatible polymer matrix, wherein the drug is an analogue related to the quinone-containing alkylating agents of a mitomycin family and wherein the drug forms a plurality of small particles in a solution. 64. The biocompatible drug release matrix of claim 63 wherein the drug is mitomycin C. 65. The biocompatible drug release matrix of claim 63 wherein the biocompatible polymer matrix comprises a plurality of sub-layers. 66. The biocompatible drug release matrix of claim 65 wherein an amount of drug suspended within the biocompatible polymer matrix varies from one sub-layer to an adjacent sub-layer. 67. The biocompatible drug release matrix of claim 65 wherein an amount of drug suspended within the biocompatible polymer matrix is approximately the same from one sub-layer to an adjacent sub-layer. 68. The biocompatible drug release matrix of claim 63 wherein the biocompatible polymer matrix comprises a single layer. 69. The biocompatible drug release matrix of claim 63 wherein the biocompatible drug release matrix is applied to a stent. 70. The biocompatible drug release matrix of claim 63 wherein the biocompatible drug release matrix is applied to a medical device. 71. The biocompatible drug release matrix of claim 70 wherein the biocompatible polymer matrix releases the drug at a rate sufficient to maintain tissue level concentrations of the drug from about 0.01 micrograms per milliliter to about 25 micrograms per milliliter of the surrounding tissue for at least two weeks after implantation of the medical device. 72. The biocompatible drug release matrix of claim 70 wherein the biocompatible polymer matrix has a concentration of the drug between about 0.1 micrograms and about 101 micrograms per millimeter of medical device length. 73. The biocompatible drug release matrix of claim 70 wherein the biocompatible polymer matrix has a concentration of the drug between about 0.02 μg/mm2 and about 2.5 μg/mm2 per medical device surface area. 74. The biocompatible drug release matrix of claim 70 wherein an initial dose of between about 10 percent to about 60 percent of the drug is delivered to the tissue in the first few days after implantation of the medical device. 75. The biocompatible drug release matrix of claim 63 wherein the drug is linked to a compound to alter the release kinetics, decrease the toxicity or enhance the potency of the drug. 76. The biocompatible drug release matrix of claim 63 wherein the drug remains part of the biocompatible polymer matrix. 77. The biocompatible drug release matrix of claim 63 wherein the drug has antibiotic properties and anti-proliferative properties. 78. The biocompatible drug release matrix of claim 63 wherein a ratio of the weight of the biocompatible polymer matrix and the drug is about 4 to about 1. 79. The biocompatible drug release matrix of claim 63 wherein the solvent is selected from the group consisting of water, saline, tetrahydrofuran, methanol, acetone, butyl acetate, cyclohexane, carbon tetrachloride, ether, chloroform, benzene, ethanol, toluene, dimethyl sulfoxide, petroleum ethers, other hydrocarbons and other organic solvents. 80. The biocompatible drug release matrix of claim 63 further comprising a metallic surface. 81. The biocompatible drug release matrix of claim 63 wherein the biocompatible polymer matrix further comprises a mixture of hydrophilic and hydrophobic polymers selected from the group consisting of polyurethanes, polyvinyl pyrrolidone, poly methyl methracrylate (PMMA), hydroxyetyl methacrylate and cellulose esters. 82. The biocompatible drug release matrix of claim 63 wherein the biocompatible polymer matrix further comprises an erodible polymer. 83. The biocompatible drug release matrix of claim 63 wherein the biocompatible polymer matrix further comprises parylene and derivatives of parylene. 84. The biocompatible drug release matrix of claim 63 wherein the biocompatible polymer matrix further comprises a thermoplastic polyurethane elastomer. 85. The biocompatible drug release matrix of claim 63 wherein the biocompatible polymer matrix further comprises a polymer selected from the group consisting of hybrid polymers, composites and polymer blends, acrylate terpolymers, tri-block polymers, polyethylene vinyl-acetate methacrylic tri-block terpolymer, ethyl-vinyl acetate, polyethyl vinyl-acetate, polybutyl methacrylic acid and polyethyl vinyl-acetate blends, polyurethanes and polyurethane-polycarbonate blends, silicone-urethane copolymers, polyvinyl pyrrolidone, polyester resins and parylene. 86. A biocompatible drug release matrix for a medical device comprising: a biocompatible drug eluting matrix comprising parylene and derivatives of parylene; and a drug incorporated into the biocompatible drug eluting matrix, wherein the biocompatible drug eluting matrix is co-solubilized with the drug in a solvent to form a solution wherein the drug forms a plurality of small particles in the solution and the solvent is evaporated from the solution to form a uniform distribution of drug in the biocompatible drug eluting matrix. 87. The biocompatible drug release matrix of claim 86 wherein the biocompatible drug eluting matrix comprises a plurality of sub-layers. 88. The biocompatible drug release matrix of claim 86 wherein the biocompatible drug eluting matrix comprises a single layer. 89. The biocompatible drug release matrix of claim 86 wherein the drug is linked to a compound to alter the release kinetics, decrease the toxicity or enhance the potency of the drug. 90. The biocompatible drug release matrix of claim 86 wherein the drug has antibiotic properties and anti-proliferative properties. 91. The biocompatible drug release matrix of claim 86 wherein the drug is an analogue related to the quinone-containing alkylating agents of a mitomycin family. 92. The biocompatible drug release matrix of claim 86 wherein the biocompatible drug eluting matrix releases the drug at a rate sufficient to maintain tissue level concentrations of the drug from about 0.01 micrograms per milliliter to about 25 micrograms per milliliter of the surrounding tissue for at least two weeks after implantation of the medical device. 93. The biocompatible drug release matrix of claim 86 wherein the biocompatible drug eluting matrix has a concentration of the drug between about 0.1 micrograms and about 101 micrograms per millimeter of medical device length. 94. The biocompatible drug release matrix of claim 86 wherein the biocompatible drug eluting matrix has a concentration of the drug between about 0.02 μg/mm2 and about 2.5 μg/mm2 per medical device surface area. 95. The biocompatible drug release matrix of claim 86 wherein an initial dose of between about 10 percent to about 60 percent of the drug is delivered to the tissue in the first few days after implantation of the medical device. 96. A biocompatible drug release matrix for a medical device comprising: a biocompatible polymer matrix comprising parylene and derivatives of parylene; and a drug suspended within the biocompatible polymer matrix, wherein the biocompatible polymer matrix is co-solubilized with the drug in a solvent to form a solution wherein the drug forms a plurality of small particles in the solution and the solvent is evaporated from the solution to form a uniform distribution of drug in the biocompatible polymer matrix. 97. The biocompatible drug release matrix of claim 96 wherein the drug is an analogue related to the quinone-containing alkylating agents of a mitomycin family. 98. The biocompatible drug release matrix of claim 96 wherein the biocompatible polymer matrix releases the drug at a rate sufficient to maintain tissue level concentrations of the drug from about 0.01 micrograms per milliliter to about 25 micrograms per milliliter of the surrounding tissue for at least two weeks after implantation of the medical device. 99. The biocompatible drug release matrix of claim 96 wherein the biocompatible polymer matrix has a concentration of the drug between about 0.1 micrograms and about 101 micrograms per millimeter of medical device length.